(3R,4S)-4-methanesulfonyloxy-3-[(pyridine-4-carbonyl)amino]azepane-1-carboxylic acid tert-butyl ester | 602277-73-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (3R,4S)-4-methanesulfonyloxy-3-[(pyridine-4-carbonyl)amino]azepane-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl (3R,4S)-4-methylsulfonyloxy-3-(pyridine-4-carbonylamino)azepane-1-carboxylate
• CAS: 602277-73-6
• 化学式: C₁₈H₂₇N₃O₆S
• 分子量: 413.495
• InChiKey: WOSZFAAWAGYWJZ-CABCVRRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  123
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (3R,4S)-4-methanesulfonyloxy-3-[(pyridine-4-carbonyl)amino]azepane-1-carboxylic acid tert-butyl ester 在 potassium tert-butylate tris(dibenzylideneacetone)dipalladium (0) 、 Ra-Ni 、 18-冠醚-6 、 氢气 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 四氢呋喃 、 甲醇 、 二甲基亚砜 为溶剂， 100.0 ℃ 、5.0 MPa 条件下， 反应 63.0h， 生成 (3R,4S)-4-{[4-(2-fluoro-3-methoxy-6-methoxymethoxybenzoyl)phenylamino]methyl}-3-[(pyridine-4-carbonyl)amino]azepane-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Structure-Based Optimization of Novel Azepane Derivatives as PKB Inhibitors

  摘要：

  Novel azepane derivatives were prepared and evaluated for protein kinase B (PKB-alpha) and protein kinase A (PKA) inhibition. The original (-)-balanol-derived lead structure (4R)-4-(2fluoro-6-hydroxy-3-methoxy-benzoyl)-benzoic acid (3R)-3-[(pyridine-4-carbonyl)aminol-azepan4-yl ester (1) (IC50 (PKB-alpha.) = 5 nM) which contains an ester moiety was found to be plasma unstable and therefore unsuitable as a drug. Based upon molecular modeling studies using the crystal structure of the complex between PKA and 1, the five compounds N-{(3R,4R)-4-[4-(2-fluoro-6-hydroxy-3-methoxy-benzoyl)-benzoylamino]-azepan-3-yl}-isonicotinamide (4), (3R,4R)-N-{4-[4-(2-fluoro-6-hydroxy-3-methoxy-benzoyl)-benzyloxy]-azepan-3-yl}-isonicotinamide (5), N-{(3R,4S)-4-[4-(2-fluoro-6-hydroxy-3-methoxy-benzoyl)-phenylamino]-methyl}-azepan-3-yl)-isonicotinamide (6), N-{(3R,4R)-4-[4-(2-fluoro-6-hydroxy-3-methoxy-benzoyl)-benzylamino]-azepan-3-yl}-isonicotinamide (7), and N-{(3R,4S)-4-(4-{trans-2-[4-(2-fluoro-6-hydroxy-3-methoxy-benzoyl)-phenyl] -vinyl}-azepan-3-yl)-isonicotinamide (8) with linkers isosteric to the ester were designed, synthesized, and tested for in vitro inhibitory activity against PKA and PKB-alpha and for plasma stability in mouse plasma.(1)Compound 4 was found to be plasma stable and highly active (IC50 (PKB-alpha) = 4 nM). Cocrystals with PKA were obtained for 4, 5, and 8 and analyzed for binding interactions and conformational changes in the ligands and protein in order to rationalize the different activities of the molecules.

  DOI：

  10.1021/jm0310479
• 作为产物：
  描述：

  (3R,4S)-3-Amino-4-hydroxy-azepane-1-carboxylic acid tert-butyl ester 在 吡啶 、 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 生成 (3R,4S)-4-methanesulfonyloxy-3-[(pyridine-4-carbonyl)amino]azepane-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Structure-Based Optimization of Novel Azepane Derivatives as PKB Inhibitors

  摘要：

  Novel azepane derivatives were prepared and evaluated for protein kinase B (PKB-alpha) and protein kinase A (PKA) inhibition. The original (-)-balanol-derived lead structure (4R)-4-(2fluoro-6-hydroxy-3-methoxy-benzoyl)-benzoic acid (3R)-3-[(pyridine-4-carbonyl)aminol-azepan4-yl ester (1) (IC50 (PKB-alpha.) = 5 nM) which contains an ester moiety was found to be plasma unstable and therefore unsuitable as a drug. Based upon molecular modeling studies using the crystal structure of the complex between PKA and 1, the five compounds N-{(3R,4R)-4-[4-(2-fluoro-6-hydroxy-3-methoxy-benzoyl)-benzoylamino]-azepan-3-yl}-isonicotinamide (4), (3R,4R)-N-{4-[4-(2-fluoro-6-hydroxy-3-methoxy-benzoyl)-benzyloxy]-azepan-3-yl}-isonicotinamide (5), N-{(3R,4S)-4-[4-(2-fluoro-6-hydroxy-3-methoxy-benzoyl)-phenylamino]-methyl}-azepan-3-yl)-isonicotinamide (6), N-{(3R,4R)-4-[4-(2-fluoro-6-hydroxy-3-methoxy-benzoyl)-benzylamino]-azepan-3-yl}-isonicotinamide (7), and N-{(3R,4S)-4-(4-{trans-2-[4-(2-fluoro-6-hydroxy-3-methoxy-benzoyl)-phenyl] -vinyl}-azepan-3-yl)-isonicotinamide (8) with linkers isosteric to the ester were designed, synthesized, and tested for in vitro inhibitory activity against PKA and PKB-alpha and for plasma stability in mouse plasma.(1)Compound 4 was found to be plasma stable and highly active (IC50 (PKB-alpha) = 4 nM). Cocrystals with PKA were obtained for 4, 5, and 8 and analyzed for binding interactions and conformational changes in the ligands and protein in order to rationalize the different activities of the molecules.

  DOI：

  10.1021/jm0310479

文献信息

• Novel azepane derivatives
  申请人：——

  公开号：US20030181716A1

  公开（公告）日：2003-09-25

  This invention provides novel azepane derivatives or pharmaceutically acceptable salts thereof, according to the general formula (I) 1 wherein the symbols are defined in the specification, as well as processes for their manufacture. The compounds according to this invention possess anti-cell proliferation activity and show an increased plasma-stability.

  该发明提供了新型的环庚烷衍生物或其药用盐，其通式如下（I）其中符号在说明书中有定义，并提供了它们的制备方法。根据该发明的化合物具有抗细胞增殖活性，并显示出增强的血浆稳定性。
• US6887864B2
  申请人：——

  公开号：US6887864B2

  公开（公告）日：2005-05-03